Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I by de Laat, Bas & de Groot, Philip G.
Autoantibodies Directed Against Domain I
of Beta2-Glycoprotein I
Bas de Laat & Philip G. de Groot
Published online: 3 November 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Patients diagnosed with the antiphospholipid
syndrome typically suffer from vascular thrombosis, preg-
nancy morbidity, or a combination of the two. Due to the
high prevalence of these clinical symptoms, the diagnosis
of antiphospholipid syndrome is almost completely depen-
dent on the detection of antiphospholipid antibodies in
patient plasma. However, not every individual with anti-
phospholipid antibodies in his or her plasma suffers from
thrombosis and/or pregnancy morbidity, which suggests the
existence of different populations of antiphospholipid anti-
bodies. Although many antigens have been identified in
relation to the antiphospholipid syndrome, β2-glycoprotein
I is regarded as clinically most significant. During the past
decade, evidence has accumulated to suggest the presence
of a dominant epitope on the first domain of β2-
glycoprotein I. Several studies have detected a specific
population of antibodies recognizing a cryptic epitope on
domain I, at least comprising arginine 39 to arginine 43. In
contrast to antibodies recognizing other domains of β2-
glycoprotein I, anti-domain I antibodies are found to be
highly associated with clinical symptoms. This review
discusses several studies that have investigated a role for
domain I within the antiphospholipid syndrome on a
predominantly diagnostic level.
Keywords Antiphospholipid syndrome.β2-glycoprotein
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Introduction
Many autoimmune diseases share clinical symptoms, which
makes it hard to distinguish them from one another based
solely on clinical manifestations. In those cases, the
diagnosis depends heavily on other diagnostic criteria (eg,
the detection of the presence of antibodies against self-
proteins). This is especially important for diagnosing a
patient with the antiphospholipid syndrome [1]. A diagno-
sis of the antiphospholipid syndrome is made on the basis
of a history of vascular thrombosis and/or pregnancy
morbidity in combination with the detection of antiphos-
pholipid antibodies as described in the official guidelines of
the International Society of Thrombosis and Haemostasis
[2]. Although the diagnosis is made clinically on the basis
of both thrombosis and pregnancy morbidity, many other
clinical symptoms have been described as being associated
with the antiphospholipid syndrome, but they are not part
of the criteria that define the disease. Due to the high
prevalence of thrombosis and pregnancy morbidity in the
general population, a heavy burden rests on the specificity
of the assays to detect the presence of antiphospholipid
antibodies.
Three assays that detect antiphospholipid antibodies are
included in the serologic criteria for the antiphospholipid
syndrome: prolongation of phospholipid-dependent coagu-
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DOI 10.1007/s11926-010-0144-8lation assays, also known as lupus anticoagulant; anti-
cardiolipin enzyme-linked immunosorbent assay (ELISA)
to detect antiphospholipid antibodies binding to the
complex cardiolipin-β2-glycoprotein I (β2GPI); and anti-
β2GPI ELISA to detect antibodies that recognize β2GPI
[2]. Several studies have shown that the results of all three
assays are very sensitive for external factors, making them
extremely difficult to standardize [3]. Of these assays, the
one that detects lupus anticoagulant is regarded as best
correlated with thrombosis, but the proper detection of
lupus anticoagulant depends heavily on the proper processing
of the blood and the quality of the plasma [4]. The
anticardiolipin ELISA is less sensitive to differences in
handling of the blood, as it does not depend on the
functionality of the antibodies (prolonging coagulation
assays) but rather simply on the binding of antibodies to
the cardiolipin-β2GPI complex coated to an ELISA plate.
The downside of this assay is the large variability between
the results obtained with assays from different manufacturers
and the relatively large number of false-positive patients,
which is probably due to direct binding to cardiolipin rather
than to the complex cardiolipin-β2GPI [5].
Therefore, the anti-β2GPI ELISA seems to be the best
choice. It is less sensitive to differences in processing of the
blood compared with lupus anticoagulant, as it measures the
binding of antibodies to β2GPI directly to the plate and not
functional activity [6]. There is no need for cardiolipin,
thereby eradicating aspecific binding of antibodies directly to
cardiolipin (which are thought not to be associated with the
antiphospholipid syndrome). Although it seems promising,
the assay is far from perfect. Several problems with the anti-
β2GPI ELISA need to be resolved to reduce false positivity,
interassay variability, and reproducibility [6]. In this review,
we discuss an important cause of these problems: the
heterogeneity of the anti-β2GPI antibodies. We advocate
that a specific subpopulation of these anti-β2GPI antibodies
directed toward domain I are the important antibodies to
measure.
Specificity of Antiphospholipid Antibodies
Many antigens have been proposed to be involved in
binding antiphospholipid antibodies, including β2GPI,
prothrombin, annexin A5, protein S, protein C, factor XI,
and factor XII [7, 8]. β2GPI is generally regarded as the
most important antigen within the antiphospholipid syn-
drome [9]. Several groups have studied the fine specificity
of anti-β2GPI antibodies, and every domain of β2GPI has
been described to bind antibodies [10]. From an immuno-
logic point of view, it is difficult to imagine a self-protein
containing many immunodominant epitopes. Many studies
have been initiated to identify this epitope, and most
evidence points to the first domain of β2GPI, also known
as domain I, as the main epitope. Iverson et al. [11] were
among the first to show that most anti-β2GPI antibodies
reacted with domain I by using domain-deletion mutants of
the protein. They continued their research by making point
mutations within domain I of β2GPI. Interestingly, they
found that most anti-β2GPI antibodies lost their reactivity
to domain I when glycine 40 or arginine 43 (which together
form a positive-charged epitope) was mutated [12]. This led
to the assumption that charge was involved in the
interaction between antibody and antigen. In 2005, we also
investigated the specificity of anti-β2GPI antibodies and
their relation to clinical significance [13]. At first, we could
not detect any binding of anti-β2GPI to domain I when
domain I was directly coated to the plate. Studying in detail
the biochemistry of domain I, we hypothesized that domain
I was coated onto the negatively hydrophilic ELISA plate,
with its positively charged epitope arginine 39-arginine 43
downward. Therefore, we tested the reactivity of anti-
β2GPI antibodies toward domain I when coated onto a
neutral hydrophobic plate. After changing ELISA plates,
we were able to detect anti-domain I antibodies. Ioannou
et al. [14] showed that not only is arginine 39-glycine 43
important for the binding of antibodies, but the epitope
comprises a much larger region on both domain I and II.
They proposed that the epitope is built up out of epitope
arginine 39-arginine 43, aspartic acid 8-aspartic acid 9, and
the interlinker region between domain I and II [14].
Binding of Anti-domain I Antibodies to β2GPI
Is Conformation Dependent
Although most evidence is directed toward domain I of
β2GPI, the question remains as to why the epitope arginine
39-glycine 43 of domain I is immunodominant. Several
theories have been published describing the induction of
autoantibodies, two of which have been extensively
investigated with respect to the antiphospholipid syndrome:
molecular mimicry and cryptic epitope exposure.
Molecular mimicry is the possibility that sequence
similarities exist between a foreign protein/peptide and a
self-protein/peptide. The presence of the foreign protein/
peptide will result in activation of autoreactive T and B
cells [15]. This can result in a loss of immunologic
tolerance toward self-proteins, thereby inducing autoimmu-
nity. Several groups have shown that an infection such as
cytomegalovirus or rubella precedes the diagnosis of the
antiphospholipid syndrome [16, 17]. In addition, it was
shown that some viruses and bacteria share amino acid
sequences and that peptides derived from viruses induced
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on the results of site-directed mutagenesis, it is now
believed that the epitope on domain I of β2GPI is not linear,
but rather three dimensional. This does not mean that
molecular mimicry cannot be involved in the induction of
antiphospholipid antibodies, but that amino acid homology
between foreign invaders and β2GPI cannot be automatically
related to the induction of antiphospholipid antibodies.
The conformation of β2GPI has been and still is of
major interest to many groups, and it is thought that the
conformation of β2GPI has consequences not only for
the binding of antiphospholipid antibodies but also for its
physiologic function in the human body [19]. Two
groups almost simultaneously published the crystal struc-
ture of β2GPI [20, 21]. Both studies displayed β2GPI as a
fishhook shape and indicated that domain V was respon-
sible for binding to a phospholipid surface, that domain I
was erected from the phospholipid surface into the
solution. In the crystal structure, epitope arginine 39-
glycine 43 is completely exposed and therefore available
for antibodies to react with it. Although some groups have
shown fluid-phase binding of anti-β2GPI antibodies to its
antigen, no research group has been able to isolate β2GPI-
antibody complexes from patients, indicating that epitope
arginine 39-glycine 43 is unavailable to react with
antiphospholipid antibodies in the fluid phase [22]. That
fluid-phase binding has been shown might be because the
β2GPI used in these studies was of a different conforma-
tion than in plasma. We hypothesized that the epitope on
domain I is cryptic and becomes exposed after interaction
of domain V with a phospholipid surface. Indeed, when
studying the structure in solution in detail by applying
small x-ray scattering, β2GPI showed an S-shaped
conformation, with a carbohydrate chain positioned on
top of domain I covering epitope arginine 39-arginine 43
[23]. This led to the hypothesis that the structure solved by
crystallization was β2GPI in its phospholipid-binding
conformation, and the structure solved by small-angle
x-ray structure was the conformation as present in plasma.
Binding of β2GPI to a phospholipid surface would induce
a conformational change in β2GPI from an S-shaped
conformation to a J-shaped conformation. When we
removed the carbohydrate chains from β2GPI, antiphos-
pholipid antibodies with reactivity toward epitope arginine
39-arginine 43 were able to bind to β2GPI in solution,
which is in contrast to fully intact β2GPI [19].
Another recently published study described a different
conformation of β2GPI by making use of electronic
microscopy [24￿￿]. Although the authors also found that
β2GPI was folded into a J shape when bound to
phospholipids, plasma-purified β2GPI appeared to have a
circular conformation in a phospholipid-free environment.
This was in contrast to the S shape described by Hammel
et al. [23]. However, as in the S-shape conformation,
epitope arginine 39-arginine 43 was also shown to be
covered, preventing antibodies from binding β2GPI in
solution. In this circular conformation, it was shown that
domain V of β2GPI was positioned on top of the interface
of domain I and II. Affinity of domain V for domains I and
II looks difficult, as both domain V and the interface of
domains I and II are positively charged. External factors
may play a role in keeping β2GPI in this circular
conformation. However, Hammel et al. [23] showed an
intermediate conformation of β2GPI between the circular
conformation and the J shape. One might hypothesize that
the carbohydrate, which is negatively charged, is positioned
on domains I and II, reversing the charge of this part of the
molecule and making it favorable for domain V to be
positioned on top of the interface of domains I and II.
Binding of β2GPI to negatively charged phospholipids
would push the carbohydrate chain away from domain V,
resulting in the J shape, with the S shape as a possible
intermediate (Fig. 1).
Based on these studies, it can be assumed that β2GPI
can adapt to different conformations and that the
conformation of β2GPI determines whether or not
antibodies against domain I can bind. In addition,
β2GPI, as in the anti-β2GPI assays, should adsorb in
the right conformation on the plate. Differences in
conformation of β2GPI preparations due to different
purification methods or coating procedures might be a
factor in the relatively large variability between assays of
different manufacturers [25￿].
Association Between Anti-domain I Antibodies
and Clinical Symptoms
As shown by several groups, anti-β2GPI antibodies are
associated with thrombosis and to a lesser extent with
pregnancy morbidity. The detection of anti-β2GPI anti-
bodies was recently included in the official criteria for
diagnosing a patient with the antiphospholipid syndrome
[2]. Still, a significant number of individuals who tested
positive for these antibodies never developed thrombosis or
pregnancy morbidity. Iverson et al. [11] showed that a
certain subpopulation of anti-β2GPI antibodies reacted
with domain I. We hypothesized that only a specific
population of anti-β2GPI antibodies was associated with
thrombosis. Therefore, we expanded the study by Iverson
et al. [11] by including the clinical significance. We
conducted a single-center study of 198 patients with
underlying autoimmune diseases [13]. We found that about
half of the patients with anti-β2GPI antibodies showed
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anti-domain I antibodies was better associated with (pre-
dominantly venous) thrombosis (OR, 18.9; 95% CI, 6.8–
53.2), compared with anti-β2GPI antibodies with reactivity
toward other domains (OR, 1.1; 95% CI, 0.4–2.8). To
confirm this result, we conducted a multicenter study
including only patients with anti-β2GPI antibodies. As in
the previous study, we found that anti-β2GPI antibodies
with reactivity toward domain I were better correlated with
thrombosis as compared with antibodies recognizing other
domains of β2GPI. Interestingly, for anti-domain I anti-
bodies, we also found a better association with pregnancy
morbidityinthemulticenterstudy(OR,2.4;95%CI,1.4–4.3).
Domain I as Clinical Drug
Treatment of the antiphospholipid syndrome is complicated
and simple at the same time. The simplicity lies in the fact
that there is only one proven method to treat patients
suffering from antiphospholipid syndrome-related throm-
bosis: anticoagulation [26]. The difficulty is in the period
Fig. 1 Model for conformational change in different published β2-
glycoprotein I (β2GPI)-based structures. The crystal structure of
β2GPI was first found and showed β2GPI in a fishhook-like shape
[20, 21]. Interestingly, using small x-ray scattering, β2GPI was found
to be in an S-shape conformation, with a carbohydrate chain on top of
the interface between domains I and II [22]. Agar et al. [24￿￿] recently
found a circular shape of β2GPI in the absence of anionic
phospholipids when applying electron microscopy. This circular
conformation could be transformed into a fishhook-like shape by
adding anionic phospholipids to the β2GPI preparation. It can be
hypothesized that all three conformations exist in the human body.
Based on this hypothesis, a model can be designed in which β2GPI
exists in a circular conformation in solution. Although domain V and
domains I and II have a predominantly positively charged surface,
they can interact due to the fact that a negative carbohydrate chain lies
in between and serves as a sort of glue. Upon binding to
phospholipids, β2GPI transitions from a circular conformation into
an S-shaped conformation. This conformation is based on the fact that
both the surface (anionic phospholipids) and the carbohydrate on top
of domains I and II are negatively charged, thereby causing domains I
and II to dissociate from domain V, which has a higher affinity for
phospholipids. Subsequently, the whole molecule erects, making
epitope arginine 39-arginine 43 available to react with anti-domain I
antibodies
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direct evidence of any time point for discontinuation of
treatment, and rethrombosis can occur at any time, but
especially during the first 6 months after discontinuation. In
addition, patients might still suffer from thrombosis despite
treatment, which would indicate deeper anticoagulation.
However, no evidence is available to justify high-intensity
treatment and is merely based on eminence [27]. Further-
more, anticoagulation has many side effects that worsen
with increased intensity of treatment.
Therefore, the idea came up not to treat thrombosis itself
but to stay one step ahead and prevent the formation or the
actions of the antibodies. Nearly a decade ago, Jones et al.
[28] published a method for eradicating anti-domain I
antibodies from the circulation. A tetramer of domain I was
constructed with an ethylene glycol-based linker named
LJP 993. Multivalent presentation of antigens in the
absence of T-cell epitopes has been described to tolerize
autoreactive B cells, meaning that a tetramer of domain I
could silence an anti-domain I antibody-producing B cell.
The same company applied this method to reduce anti-
double-stranded DNA antibodies to treat lupus nephritis
[29]. Despite big hopes, none of these products are on the
market now, all for different reasons.
Despite silencing anti-domain I-producing B cells,
domain I could also be used to capture and neutralize
antiphospholipid antibodies. Ioannou et al. [30￿￿] recently
conducted a study in which they investigated this method of
treatment. Mice were injected with IgG purified from
patients diagnosed with the antiphospholipid syndrome or
from healthy controls. In addition, domain I containing a
mutation (D8S/D9G), thereby enhancing fluid-phase binding
of antibodies, was injected into the mice. After standardized
vessel injury, mice injected with antiphospholipid-related IgG
displayed increased thrombus size, which could be inhibited
by the domain I mutant.
One of the hesitations when conducting studies in which
the antigen itself is injected is the possibility of further
activating the immune system, resulting in increased
antibody levels. It has been shown that one of the T-cell
epitopes is present on domain V, possibly decreasing the
risk of potentiating the disease, but it is not known whether
domain I itself contains a T-cell epitope [31]. We recently
showed at the Biannual Congress of the International
Society of Thrombosis and Haemostasis that injecting mice
with domain I in the absence of Freund’s adjuvant does
result in anti-domain I antibodies [32￿￿]. Therefore, one
should be extremely cautious in extrapolating these data to
treatment options in clinical practice.
Conclusions
The presence of antibodies toward β2GPI does not
automatically mean that an individual will suffer from
antiphospholipid syndrome-related symptoms. The assay to
detect the antibodies has many pitfalls; thus, we do not
know when we should consider a result positive. We know
now that there are different subpopulations of antibodies
that recognize β2GPI. Together with the high prevalence of
thrombosis and pregnancy morbidity, it is difficult to make
a diagnosis of antiphospholipid syndrome for certain. In
this respect, the detection of anti-domain I antibodies could
be an addition to the current serologic criteria, as it has a
Table 1 Differences between the anti-domain I assay and the anti-β2GPI ELISA
Anti-domain I assay Anti-β2GPI ELISA
Conformation of β2GPI Conformation independent, as only
domain I is coated
Binding of antibodies to β2GPI depends on whether
epitope R39–R43 is exposed
Charge of the ELISA plate A neutral plate is needed to prevent
epitope R39–R43 from being coated
downward to the plate
A negative plate is needed, which is thought to induce
a conformational change and enables 1 antibody to
bind 2 molecules
Specificity and sensitivity High specificity, but it is not known
whether other pathogenic antibody
populations are missed
High sensitivity, but a mediocre specificity, as a
significant number of positive patients do not
develop APS-related clinical symptoms
Source of protein Domain I is produced and thereby
recombinant
β2GPI can be purified from human or bovine plasma,
or produced recombinant. It is not known whether
there are differences in conformation between the
different sources
Purification Domain I contains a his-tag and
is purified via nickel-Sepharose
a
β2GPI can be purified by applying different techniques;
the influence of the different techniques on the
conformation of β2GPI is not known
APS antiphospholipid syndrome, ELISA enzyme-linked immunosorbent assay, GPI glycoprotein I
aSigma-Aldrich (St. Louis, MO)
74 Curr Rheumatol Rep (2011) 13:70–76much higher specificity for the clinical manifestations than
the standard anti-β2GPI ELISA [13].
A sm e n t i o n e dp r e v i o u s l y ,d o m a i nIm a ya l s ob eo f
value in standardizing the anti-β2GPI ELISA. Many
attempts have been made to standardize the anti-β2GPI
ELISA without success [5, 33, 34]. One of the reasons
may be that binding of anti-domain I antibodies is
dependent on the conformation of β2GPI. Therefore, the
preparation and coating of β2GPI to ELISA trays is of
major importance to the results of the assay. In addition,
β2GPI needs to be coated onto a negatively charged plate
in order to unfold. These problems can be overcome when
using domain I as a coating, as it does not need a
conformational change (Table 1). Therefore, it is less
sensitive for in vitro artifacts.
It is too soon to replace the anti-β2GPI ELISA with the
anti-domain I assay, as there is still the possibility that other
populations of thrombosis-related antibodies are present.
Moreover, the results obtained should be confirmed in
larger cohorts. In fact, some authors suggest that in addition
to domain I, domain IV is also a candidate for binding
thrombosis-related antibodies [35]. It is possible that certain
symptoms are associated with certain subpopulations of
antibodies. We have shown that anti-domain I antibodies
highly associate with predominantly venous thrombosis.
However, it is hard to believe that this population of
antibodies causes all the thrombotic complications observed
in patients diagnosed with the antiphospholipid syndrome.
It is tempting to further investigate whether one population
of antibodies can explain all the clinical manifestations or
whether different subpopulations are responsible for the
various events present in the antiphospholipid syndrome
[36].
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